- Home
- EDF vs PROK Comparison
EDF vs PROK Comparison
Compare EDF & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDF
- PROK
- Stock Information
- Founded
- EDF 2010
- PROK 2015
- Country
- EDF United States
- PROK United States
- Employees
- EDF N/A
- PROK N/A
- Industry
- EDF Investment Managers
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EDF Finance
- PROK Health Care
- Exchange
- EDF Nasdaq
- PROK Nasdaq
- Market Cap
- EDF 148.8M
- PROK 85.5M
- IPO Year
- EDF N/A
- PROK N/A
- Fundamental
- Price
- EDF $5.06
- PROK $0.61
- Analyst Decision
- EDF
- PROK Hold
- Analyst Count
- EDF 0
- PROK 3
- Target Price
- EDF N/A
- PROK $3.50
- AVG Volume (30 Days)
- EDF 160.6K
- PROK 1.6M
- Earning Date
- EDF 01-01-0001
- PROK 08-08-2025
- Dividend Yield
- EDF 13.14%
- PROK N/A
- EPS Growth
- EDF N/A
- PROK N/A
- EPS
- EDF N/A
- PROK N/A
- Revenue
- EDF N/A
- PROK $306,000.00
- Revenue This Year
- EDF N/A
- PROK $54.34
- Revenue Next Year
- EDF N/A
- PROK N/A
- P/E Ratio
- EDF N/A
- PROK N/A
- Revenue Growth
- EDF N/A
- PROK N/A
- 52 Week Low
- EDF $3.51
- PROK $0.46
- 52 Week High
- EDF $5.50
- PROK $2.59
- Technical
- Relative Strength Index (RSI)
- EDF 60.99
- PROK 45.99
- Support Level
- EDF $4.96
- PROK $0.64
- Resistance Level
- EDF $5.07
- PROK $0.90
- Average True Range (ATR)
- EDF 0.06
- PROK 0.14
- MACD
- EDF -0.00
- PROK -0.02
- Stochastic Oscillator
- EDF 76.47
- PROK 26.33
About EDF Virtus Stone Harbor Emerging Markets Income Fund of Beneficial Interest
Virtus Stone Harbor Emerging Markets Income Fund is a closed-end management investment company. Its investment objective is to maximize total return, which consists of income from its investments and capital appreciation. The Fund normally will invest at least 80% of its net assets (plus any borrowings for investment purposes) in emerging markets securities.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.